Literature DB >> 10695721

Autoimmune maintenance and neuroprotection of the central nervous system.

I R Cohen1, M Schwartz.   

Abstract

The genesis of immune privilege high in the evolutionary tree suggests that immune privilege is necessary, if not advantageous for the progressive development of the CNS. Upon reaching a certain degree of complexity, it seems as if the CNS was obliged to restrain the immune system from penetrating the blood-brain barrier. CNS autoimmunity against myelin proteins is known to be a contributory factor in the pathophysiology of multiple sclerosis and in the animal model of experimental autoimmune encephalomyelitis (EAE) (Wekerle, 1993). Such autoimmunity has therefore been regarded as detrimental and hence obviously undesirable. However, recent findings in our laboratory suggest that T-cell autoimmunity to CNS self-antigens (Moalem et al., 1999), if expressed at the right time and the right place, can do much good in the CNS. We shall review the experiments briefly, and then discuss their implications for our understanding of immune privilege and CNS maintenance after injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695721     DOI: 10.1016/s0165-5728(99)00190-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  Protective autoimmunity is a physiological response to CNS trauma.

Authors:  E Yoles; E Hauben; O Palgi; E Agranov; A Gothilf; A Cohen; V Kuchroo; I R Cohen; H Weiner; M Schwartz
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

Review 2.  Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?

Authors:  N C Derecki; E Privman; J Kipnis
Journal:  Mol Psychiatry       Date:  2010-02-23       Impact factor: 15.992

Review 3.  Debate: "is increasing neuroinflammation beneficial for neural repair?".

Authors:  Keith A Crutcher; Howard E Gendelman; Jonathan Kipnis; J Regino Perez-Polo; V H Perry; Phillip G Popovich; Lynne C Weaver
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

4.  Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies.

Authors:  J Fisher; H Levkovitch-Verbin; H Schori; E Yoles; O Butovsky; J F Kaye; A Ben-Nun; M Schwartz
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

5.  Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis.

Authors:  Xiaohua Xu; Aleksandar Denic; Arthur E Warrington; Allan J Bieber; Moses Rodriguez
Journal:  J Clin Immunol       Date:  2012-09-19       Impact factor: 8.317

6.  Nucleic Acid Vaccine Targeting Nogo-66 Receptor and Paired Immunoglobulin-Like Receptor B as an Immunotherapy Strategy for Spinal Cord Injury in Rats.

Authors:  Xiu-Min Lu; Min Mao; Lan Xiao; Ying Yu; Mei He; Guo-Yan Zhao; Jun-Jie Tang; Shuang Feng; Sen Li; Cheng-Ming He; Yong-Tang Wang
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

7.  Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: an event resistant to glucocorticoid inhibition.

Authors:  Priscila O Barros; Thais B Ferreira; Morgana M M Vieira; Carla Renata M Almeida; Carlos Fernando Araújo-Lima; Renato G Silva-Filho; Joana Hygino; Regis M Andrade; Arnaldo F Andrade; Cleonice A Bento
Journal:  J Clin Immunol       Date:  2010-09-24       Impact factor: 8.317

Review 8.  T-cell cytokines in injury-induced neural damage and repair.

Authors:  Michael Schroeter; Sebastian Jander
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

9.  Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders.

Authors:  Sharifia Wills; Maricel Cabanlit; Jeff Bennett; Paul Ashwood; David G Amaral; Judy Van de Water
Journal:  Brain Behav Immun       Date:  2008-07-30       Impact factor: 7.217

10.  Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.

Authors:  Alon Monsonego; Victor Zota; Arnon Karni; Jeffery I Krieger; Amit Bar-Or; Gal Bitan; Andrew E Budson; Reisa Sperling; Dennis J Selkoe; Howard L Weiner
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.